EBV Screening for the Early Detection of Nasopharyngeal Carcinoma
EBV screening for the early detection of nasopharyngeal carcinoma in China demonstration project includes a group of approximately 52,000 men and women ages 30-69 recruited into the active screening arm of a community‑randomized trial to evaluate the impact of EBV‑based antibody screening on NPC mortality rates.
Evidence level: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.
Related signals
- Anti‑PD‑1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double‑blind phase 3 study
- Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma
- Nasopharyngeal Cancer
- Hierarchical dynamic model for risk‑stratified screening of nasopharyngeal carcinoma
- Expert consensus on the role of immunotherapy in nasopharyngeal carcinoma: clinical and economic perspectives from the GCC region